InterMune Inc. (Nasdaq: ITMN) reported positive results from an ASCEND phase III study of pirfenidone sending the stock price soaring $4.98 to $39.29.
InterMune reports positive trial results
May 19, 2014 at 13:37 PM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.